

# Pharmacy BULLETIN BOARD

Industry Issue ■ Monday February 10, 2014.

**UriSec®** emollient creams and lotion are patient friendly formulations ideal for winter dryness and itchy skin.

Product	NPN	Sizes	Odan Code	UPC
UriSec® 10% Cream	80005397	75 g	38075	776097380751
		120 g	38045	776097380454
UriSec 12% Lotion	00514896	250 mL	230J	776097230254
UriSec® 22% Cream	00396125	120 g	220Q	776097220453
		225 g	220C	776097220651
		454 g	220R	776097220859
UriSec® 40 Cream	80005531	15 g	45014	776097450140
		30 g	45028	776097450287
		100 g	45067	776097450676

**UriSec®** products are prescribed by Dermatologists and Physicians and are used by both patients and hospitals across Canada.

To order, please contact your wholesaler or Odan at 1-800-387-9342 or by e-mail at [info@odanlab.com](mailto:info@odanlab.com). You can also visit our website at [www.odanlab.com](http://www.odanlab.com).



UriSec® is a registered trademark of Odan Laboratories Ltd.

## ■ FROM THE NEWSWIRE ■

**TORONTO:** Janssen Inc. announced that the results of the two pivotal clinical studies from Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment (PURSUIT) have been published in Gastroenterology. The studies evaluate SIMPONI® (golimumab) induction and maintenance therapy in anti-tumor necrosis factor (TNF) naïve adults with moderate to severe ulcerative colitis (UC), who had an inadequate response to or had failed to tolerate conventional treatments.

**TORONTO:** Men with metastatic castration-resistant prostate cancer (mCRPC) in Québec now have access to a therapy that can be used prior to chemotherapy. Effective February 3, 2014, the province has added ZYTIGA® (abiraterone acetate) to the public drug formulary for the treatment of mCRPC in men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT).

**KIRKLAND, QC:** A new treatment option is now available for Canadian allergic rhinitis sufferers. GRASTEK™ (Standardized Allergenic Extract, Timothy Grass (*Phleum pratense*) Sublingual Tablet), an immunotherapy treatment to help manage grass allergies, is indicated for reducing the signs and symptoms of moderate to severe seasonal Timothy and related grass pollen induced allergic rhinitis (with or without conjunctivitis) in adults and children five years of age and older confirmed by clinically relevant symptoms for at least two pollen seasons and a positive skin prick test and/or a positive titre to *Phleum pratense* specific IgE; and who have responded inadequately, or are intolerant to conventional pharmacotherapy.

**TORONTO:** Janssen Inc. announced that Health Canada approved STELARA® (ustekinumab) for the treatment of adult patients with active psoriatic arthritis, alone or in combination with methotrexate. It is estimated that approximately 30 per cent of Canadians living with psoriasis may develop psoriatic arthritis, a chronic autoimmune disease characterized by both joint inflammation and psoriasis skin lesions. The condition is associated with reduced quality of life and increased mortality.

**MONTREAL:** Roche Diagnostics Canada is pleased to announce the indication extension of its CoaguChek® XS PT Test Strip on the List of Medications of the Régie de l'assurance maladie du Québec (RAMQ) to all patients capable of performing PT/INR Patient Self-Testing (PST) or Patient Self-Management (PSM) using the CoaguChek® XS coagulometer.

**To include your communication in the next issue, please contact: Health Response**

T: 416-863-5403 | F: 416-863-9620 | [hrc@healthresponse.ca](mailto:hrc@healthresponse.ca)

**Next Issue: Monday February 24<sup>th</sup>, 2014**

Deadline: Thursday February 20<sup>th</sup>, 2014